IN2015DN00450A - - Google Patents
Info
- Publication number
- IN2015DN00450A IN2015DN00450A IN450DEN2015A IN2015DN00450A IN 2015DN00450 A IN2015DN00450 A IN 2015DN00450A IN 450DEN2015 A IN450DEN2015 A IN 450DEN2015A IN 2015DN00450 A IN2015DN00450 A IN 2015DN00450A
- Authority
- IN
- India
- Prior art keywords
- combination
- inhibitor
- administering
- treating
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A pharmaceutical combination comprising (a) a B Raf inhibitor (b) a EGFR inhibitor and optionally (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680473P | 2012-08-07 | 2012-08-07 | |
PCT/US2013/053619 WO2014025688A1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00450A true IN2015DN00450A (en) | 2015-06-26 |
Family
ID=48980368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN450DEN2015 IN2015DN00450A (en) | 2012-08-07 | 2013-08-05 |
Country Status (39)
Country | Link |
---|---|
US (1) | US9474754B2 (en) |
EP (2) | EP2882440B1 (en) |
JP (3) | JP6342396B2 (en) |
KR (1) | KR102112885B1 (en) |
CN (1) | CN104519887B (en) |
AR (1) | AR092045A1 (en) |
AU (1) | AU2013299841B8 (en) |
CA (1) | CA2879548C (en) |
CL (1) | CL2015000294A1 (en) |
CO (1) | CO7200273A2 (en) |
CY (1) | CY1122143T1 (en) |
DK (1) | DK2882440T3 (en) |
EA (1) | EA028420B1 (en) |
EC (1) | ECSP15008695A (en) |
ES (1) | ES2717911T3 (en) |
GT (1) | GT201500025A (en) |
HK (2) | HK1204976A1 (en) |
HR (1) | HRP20190537T1 (en) |
HU (1) | HUE042877T2 (en) |
IL (1) | IL236934B (en) |
IN (1) | IN2015DN00450A (en) |
JO (1) | JOP20130236B1 (en) |
LT (1) | LT2882440T (en) |
MA (1) | MA37829A1 (en) |
MX (1) | MX359403B (en) |
MY (1) | MY176031A (en) |
NZ (1) | NZ703940A (en) |
PE (2) | PE20191655A1 (en) |
PH (1) | PH12015500246A1 (en) |
PL (1) | PL2882440T3 (en) |
PT (1) | PT2882440T (en) |
RS (1) | RS58734B1 (en) |
SG (1) | SG11201500321YA (en) |
SI (1) | SI2882440T1 (en) |
TN (1) | TN2015000027A1 (en) |
TR (1) | TR201904980T4 (en) |
TW (1) | TWI607754B (en) |
UA (1) | UA115786C2 (en) |
WO (1) | WO2014025688A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2882440T3 (en) * | 2012-08-07 | 2019-05-06 | Novartis Ag | PHARMACEUTICAL COMBINATIONS INCLUDING A B-RAF INHIBITOR, EGFR INHIBITOR AND, optionally, PI3K-ALFA INHIBITOR |
SI2976106T1 (en) | 2013-03-21 | 2021-08-31 | Array Biopharma Inc. | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
WO2015193212A1 (en) * | 2014-06-16 | 2015-12-23 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
CN107921037A (en) * | 2015-08-28 | 2018-04-17 | 诺华股份有限公司 | The drug regimen of ALPELISIB and B the RAF inhibitor dabrafenibs of inhibitor containing PI3K;Application of the combination in cancer is treated or prevented |
WO2017037578A2 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Combination therapy |
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
EP3463345B1 (en) | 2016-06-03 | 2022-11-02 | Array BioPharma Inc. | Pharmaceutical combinations |
CA3037456A1 (en) * | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
US20200237773A1 (en) * | 2017-08-03 | 2020-07-30 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
AU2019353144B2 (en) | 2018-10-05 | 2023-11-16 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
TW202043225A (en) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor |
WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023145530A1 (en) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | Therapeutic agent for cancer |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP2010523670A (en) | 2007-04-10 | 2010-07-15 | エクセリクシス, インク. | Method of treatment using pyridopyrimidinone inhibitor of PI3K alpha |
UA104147C2 (en) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Pyrrolidine dicarboxylic acid derivative and use thereof in the treatment of proliferative diseases |
MY165154A (en) | 2009-08-24 | 2018-02-28 | Genentech Inc | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
AR077975A1 (en) * | 2009-08-28 | 2011-10-05 | Irm Llc | PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
CA2777561A1 (en) * | 2009-10-12 | 2011-04-21 | Glaxosmithkline Llc | Combination |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
MX360157B (en) * | 2010-11-08 | 2018-10-24 | Novartis Ag | Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members. |
AU2012335665A1 (en) | 2011-11-10 | 2014-07-03 | Memorial Sloan-Kettering Cancer Center | Treatment of ovarian cancer with 2-amino-4H-naphtho[1,2-B]pyran-3-carbonitriles |
AU2012335663B2 (en) * | 2011-11-11 | 2015-12-24 | Array Biopharma Inc. | Method of treating a proliferative disease |
DK2882440T3 (en) * | 2012-08-07 | 2019-05-06 | Novartis Ag | PHARMACEUTICAL COMBINATIONS INCLUDING A B-RAF INHIBITOR, EGFR INHIBITOR AND, optionally, PI3K-ALFA INHIBITOR |
-
2013
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/en active
- 2013-08-05 SI SI201331387T patent/SI2882440T1/en unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/en active IP Right Grant
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/en active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/en unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/en unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/en unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en active Application Filing
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/en unknown
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/en active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/en unknown
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/en unknown
- 2013-08-05 PT PT13748243T patent/PT2882440T/en unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 EA EA201590332A patent/EA028420B1/en not_active IP Right Cessation
- 2013-08-05 AR ARP130102776A patent/AR092045A1/en not_active Application Discontinuation
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/en active IP Right Grant
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/en unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/en not_active Application Discontinuation
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/en active Active
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-06 TW TW102128165A patent/TWI607754B/en active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/en active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/en unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/en unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/en unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/en unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/en unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/en unknown
- 2015-06-18 HK HK15105815.5A patent/HK1204976A1/en unknown
- 2015-11-03 HK HK15110834.2A patent/HK1211831A1/en unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/en active Active
-
2019
- 2019-03-19 HR HRP20190537TT patent/HRP20190537T1/en unknown
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/en unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00450A (en) | ||
IN2015DN00376A (en) | ||
MX2020004023A (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia. | |
EA201500314A1 (en) | DOSAGE FORMS OF ENZALUTAMIDE | |
PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MX2021010672A (en) | Diagnosis and therapy of cancer involving cancer stem cells. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
EA201491330A1 (en) | THERAPEUTICALLY ACTIVE CONNECTIONS AND METHODS OF THEIR USE | |
RU2018145985A (en) | ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS | |
MX348941B (en) | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer. | |
MX360189B (en) | Combination therapy for the treatment of glioblastoma. | |
MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
EA201491836A1 (en) | METHODS OF CANCER TREATMENT USING PI3K INHIBITOR AND MEK INHIBITOR | |
MX2017001983A (en) | Rspo1 binding agents and uses thereof. | |
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
EA201491695A1 (en) | TREATMENT OF CANCER TOR-KINASE INHIBITORS | |
UA86338U (en) | Method for treating gestational diabetes |